The Journal of Immunology, Vol 155, Issue 12 5655-5662, Copyright © 1995 by American Association of Immunologists

ARTICLES

Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles

DA Kirschmann, KL Duffin, CE Smith, JK Welply, SC Howard, BD Schwartz and SL Woulfe
Department of Immunology, G. D. Searle/Monsanto Corporate Research, St. Louis, MO 63198, USA.

Naturally processed peptides from immunoaffinity-purified HLA- DRB1*0401, -DRB1*0404 (rheumatoid arthritis (RA)-associated), and - DRB1*0402 (non-RA-associated) molecules were analyzed by capillary liquid chromatography and mass spectrometry. The molecular weights observed for more than 60 eluted peptides from each HLA-DR protein ranged from 788 to 3535 atomic mass units, corresponding to peptides 7 to 32 amino acids in length. Sequencing of more than 60 of the abundant peptides revealed nested sets of peptides that were derived from only 12 different proteins. The majority of these proteins were membrane- associated (HLA class I, class II, and Ig molecules). Synthetic peptides, corresponding to endogenous peptide sequences, bound with high affinity (5 to 80 nM) to the HLA-DR molecules from which they were eluted. In addition, most were promiscuous binding peptides in that they also bound to other HLA-DR molecules. Truncations of eluted peptide sequences and alanine scanning mutational analysis of a Mycobacterium leprae peptide were used to identify the peptide residues involved in binding to DRB1*0404 and DRB1*0402 molecules. Furthermore, an invariant chain peptide was eluted from the DRB1*0402 molecules but not from the RA-associated molecules. The lack of invariant chain peptides from DRB1*0401 and DRB1*0404 molecules may contribute to the loading of autoantigen peptides into these molecules and to their association with disease.

This article has been cited by other articles:

				V. Taneja, M. Behrens, E. Basal, J. Sparks, M. M. Griffiths, H. Luthra, and C. S. David Delineating the Role of the HLA-DR4 "Shared Epitope" in Susceptibility versus Resistance to Develop Arthritis J. Immunol., August 15, 2008; 181(4): 2869 - 2877. [Abstract] [Full Text] [PDF]

				N A Shadick, J E Heller, M E Weinblatt, N E Maher, J Cui, G Ginsburg, J Coblyn, R Anderson, D H Solomon, R Roubenoff, et al. Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis Ann Rheum Dis, November 1, 2007; 66(11): 1497 - 1502. [Abstract] [Full Text] [PDF]

				I. G. Ovsyannikova, K. L. Johnson, D. C. Muddiman, R. A. Vierkant, and G. A. Poland Identification and Characterization of Novel, Naturally Processed Measles Virus Class II HLA-DRB1 Peptides J. Virol., January 1, 2004; 78(1): 42 - 51. [Abstract] [Full Text] [PDF]

				V. Taneja, N. Taneja, M. Behrens, S. Pan, T. Trejo, M. Griffiths, H. Luthra, and C. S. David HLA-DRB1*0402 (DW10) Transgene Protects Collagen- Induced Arthritis-Susceptible H2Aq and DRB1*0401 (DW4) Transgenic Mice from Arthritis J. Immunol., October 15, 2003; 171(8): 4431 - 4438. [Abstract] [Full Text] [PDF]

				C. Ma, P. E. Whiteley, P. M. Cameron, D. C. Freed, A. Pressey, S.-L. Chen, B. Garni-Wagner, C. Fang, D. M. Zaller, L. S. Wicker, et al. Role of APC in the Selection of Immunodominant T Cell Epitopes J. Immunol., December 15, 1999; 163(12): 6413 - 6423. [Abstract] [Full Text] [PDF]

				M. Fridkis-Hareli, E. F. Rosloniec, L. Fugger, and J. L. Strominger Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones PNAS, October 13, 1998; 95(21): 12528 - 12531. [Abstract] [Full Text] [PDF]

				S. L. Woulfe, C. P. Bono, M. L. Zacheis, J. K. Welply, D. A. Kirschmann, T. A. Baudino, Y. Wang, D. A. Stone, G. J. Hanson, J. L. Vuletich, et al. A Peptidomimetic that Specifically Inhibits Human Leukocyte Antigen DRB1*0401-restricted T Cell Proliferation J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 663 - 669. [Abstract] [Full Text]

				M. Gueguen and E. O. Long Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen PNAS, December 10, 1996; 93(25): 14692 - 14697. [Abstract] [Full Text] [PDF]